Role of Microenvironment in Resistance to Therapy in AML

DOI: 10.1007/s11899-015-0253-6
Current Hematologic Malignancy Reports, 2015, 10, 96-103.

#	Paper	IF	Citations
71	Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 2773-80	4	15
70	The Hematopoietic Niche in Myeloproliferative Neoplasms. *Mediators of Inflammation*, **2015**, 2015, 347270	4.3	14
69	DNA Damage Response/Repair in Cancer Stem Cells Potential vs. Controversies. **2015**,		4
68	Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. *Vaccines*, **2016**, 4,	5.3	33
67	Modeling the Pro-inflammatory Tumor Microenvironment in Acute Lymphoblastic Leukemia Predicts a Breakdown of Hematopoietic-Mesenchymal Communication Networks. *Frontiers in Physiology*, **2016**, 7, 349	4.6	18
66	HIF-1 inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia. *Cancer Biology and Therapy*, **2016**, 17, 625-34	4.6	24
65	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. *Cancer Cell*, **2016**, 29, 574-586	24.3	154
64	Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. *Blood*, **2016**, 128, 1260-9	2.2	75
63	Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma. *Expert Opinion on Drug Discovery*, **2016**, 11, 1093-1109	6.2	20
62	Induction of Multidrug Resistance of Acute Myeloid Leukemia Cells by Cocultured Stromal Cells via Upregulation of the PI3K/Akt Signaling Pathway. *Oncology Research*, **2016**, 24, 215-23	4.8	14
61	Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?. *European Journal of Haematology*, **2016**, 96, 211-21	3.8	16
60	A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. *Blood Cancer Journal*, **2017**, 7, e542	7	35
59	Predicting Chemotherapy Resistance in AML. *Current Hematologic Malignancy Reports*, **2017**, 12, 530-536	4.4	13
58	MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells. *Cancer Science*, **2017**, 108, 685-695	6.9	15
57	GSK-3 as a novel prognostic indicator in leukemia. *Advances in Biological Regulation*, **2017**, 65, 26-35	6.2	26
56	Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2017**, 1868, 183-198	11.2	25
55	Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening. *Tissue Engineering - Part C: Methods*, **2017**, 23, 72-85	2.9	22

54	Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1765-1780	4	57
53	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. *Oncotarget*, **2017**, 8, 67639-67650	3.3	20
52	The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. *Oncotarget*, **2017**, 8, 2261-2274	3.3	30
51	Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic Progression at the Expense of Normal Lymphopoiesis. *Frontiers in Immunology*, **2016**, 7, 666	8.4	22
50	Periarteriolar Glioblastoma Stem Cell Niches Express Bone Marrow Hematopoietic Stem Cell Niche Proteins. *Journal of Histochemistry and Cytochemistry*, **2018**, 66, 155-173	3.4	27
49	Alginate foam-based three-dimensional culture to investigate drug sensitivity in primary leukaemia cells. *Journal of the Royal Society Interface*, **2018**, 15,	4.1	4
48	CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. *Leukemia and Lymphoma*, **2018**, 59, 821-828	1.9	8
47	Complete Remission of a Refractory Acute Myeloid Leukemia with Myelodysplastic- and Monosomy 7-Related Changes after a Combined Conditioning Regimen of Plerixafor, Cytarabine and Melphalan in a 4-Year-Old Boy: A Case Report and Review of Literature. *Cancers*, **2018**, 10,	6.6	
46	Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in -mutated acute myeloid leukemias: from concept to clinical trial. *Haematologica*, **2018**, 103, 1642-1653	6.6	23
45	Identification of prognostic genes in the acute myeloid leukemia immune microenvironment based on TCGA data analysis. *Cancer Immunology, Immunotherapy*, **2019**, 68, 1971-1978	7.4	47
44	Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment. *Advances in Cancer Research*, **2019**, 141, 213-253	5.9	6
43	Differences in Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia. *Mediterranean Journal of Hematology and Infectious Diseases*, **2019**, 11, e2019016	3.2	3
42	Merger of dynamic two-photon and phosphorescence lifetime microscopy reveals dependence of lymphocyte motility on oxygen in solid and hematological tumors. **2019**, 7, 78		26
41	Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells. *Experimental Cell Research*, **2019**, 376, 114-123	4.2	3
40	Normal and leukemic stem cell niche interactions. *Current Opinion in Hematology*, **2019**, 26, 249-257	3.3	6
39	CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. *Blood*, **2019**, 133, 588-599	2.2	53
38	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. *Leukemia Research*, **2019**, 76, 1-10	2.7	9
37	Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome. *Drug Resistance Updates*, **2020**, 53, 100730	23.2	5

36	Small Molecule Inhibitors of Microenvironmental Wnt/Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia. *Cancers*, **2020**, 12,	6.6	7
35	Cadherins, Selectins, and Integrins in CAM-DR in Leukemia. *Frontiers in Oncology*, **2020**, 10, 592733	5.3	9
34	Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2020**, 1874, 188387	11.2	5
33	Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia. *Cancers*, **2020**, 12,	6.6	5
32	mTOR Regulation of Metabolism in Hematologic Malignancies. *Cells*, **2020**, 9,	7.9	5
31	Rho GTPases: Promising candidates for overcoming chemotherapeutic resistance. *Cancer Letters*, **2020**, 475, 65-78	9.9	5
30	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. *Blood Advances*, **2020**, 4, 274-286	7.8	18
29	Repurposing of artemisinin-type drugs for the treatment of acute leukemia. *Seminars in Cancer Biology*, **2021**, 68, 291-312	12.7	4
28	Remodeling of Bone Marrow Niches and Roles of Exosomes in Leukemia. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
27	Chimerism, the Microenvironment and Control of Leukemia. *Frontiers in Immunology*, **2021**, 12, 652105	8.4	1
26	Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia. *Clinical and Translational Oncology*, **2021**, 23, 2141-2154	3.6	1
25	Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression. *Leukemia*, **2021**, 35, 2799-2812	10.7	6
24	Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis. *Cancers*, **2021**, 13,	6.6	
23	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. *Blood*, **2021**,	2.2	3
22	Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected. *Mutagenesis*, **2021**, 36, 419-428	2.8	1
21	The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 599276	5.7	6
20	Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia. *Current Oncology Reports*, **2020**, 22, 27	6.3	25
19	Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. *Critical Reviews in Oncology/Hematology*, **2020**, 152, 102993	7	6

18	Stress and catecholamines modulate the bone marrow microenvironment to promote tumorigenesis. *Cell Stress*, **2019**, 3, 221-235	5.5	12
17	A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. *Cells*, **2021**, 10,	7.9	3
16	Establishment of Prognosis Model in Acute Myeloid Leukemia Based on Hypoxia Microenvironment, and Exploration of Hypoxia-Related Mechanisms. *Frontiers in Genetics*, **2021**, 12, 727392	4.5	1
15	Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells. *Cancers*, **2021**, 13,	6.6	1
14	Integrated - and -Glycomics of Acute Myeloid Leukemia (AML) Cell Lines. *Cells*, **2021**, 10,	7.9	1
13	Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells. *British Journal of Haematology*, **2021**,	4.5	2
12	Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.. *Drug Resistance Updates*, **2022**, 61, 100805	23.2	4
11	Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.. *Frontiers in Oncology*, **2022**, 12, 807266	5.3	1
10	Therapeutic resistance to FLT3 inhibition is driven by a novel ATM/mTOR pathway regulating oxidative phosphorylation.		
9	Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches.. *Stem Cell Reviews and Reports*, **2022**, 1	7.3	0
8	Mesenchymal stroma/stem cells: Haematologists friend or foe?. *British Journal of Haematology*,	4.5	
7	The Increase in the Drug Resistance of Acute Myeloid Leukemia THP-1 Cells in High-Density Cell Culture Is Associated with Inflammatory-like Activation and Anti-Apoptotic Bcl-2 Proteins. *International Journal of Molecular Sciences*, **2022**, 23, 7881	6.3	0
6	A Systems Biology- and Machine Learning-Based Study to Unravel Potential Therapeutic Mechanisms of Midostaurin as a Multitarget Therapy on FLT3-Mutated AML. *BioMedInformatics*, **2022**, 2, 375-397		
5	Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation. 11,		0
4	FLT3 inhibitors upregulate CXCR4 and E-selectin ligands through suppression of ERK in AML and combined inhibition of CXCR4/E-selectin enhances anti-leukemia efficacy of FLT3-targeted therapy.		0
3	m6A RNA methylation regulators predict prognosis and indicate characteristics of tumour microenvironment infiltration in acute myeloid leukaemia. 1-20		0
2	Cancer Stem Cells: Biology and Therapeutic Implications. **2022**, 53, 770-784		1
1	FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.		0